BioSpace News Archive

Juvenescence is pleased to announce the successful closure of its $100 million Series B round, including a total of $10 million from its founders and a further $10 million each from four cornerstone investors, including Grok Ventures, the investment company of Mike Cannon-Brookes, and Michael Spencer’s private investment company, IPGL.

Boston Scientific Corporation announced the completion of its acquisition of BTG plc. pursuant to the previously announced scheme of arrangement.

The financing will further support MolecuLight’s commercial expansion for the growing global demand for its MolecuLight i:X device.